Regeneron Pharmaceuticals Inc (REGN)

Working capital turnover

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	US$ in thousands	14,202,000	13,044,200	12,113,500	16,014,400	8,440,200
Total current assets	US$ in thousands	18,660,900	19,479,200	15,884,100	14,014,900	9,779,100
Total current liabilities	US$ in thousands	3,944,300	3,423,400	3,141,300	3,932,500	2,697,400
Working capital turnover		0.97	0.81	0.95	1.59	1.19

December 31, 2024 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $14,202,000K ÷ ($18,660,900K – $3,944,300K)
= 0.97

The working capital turnover ratio for Regeneron Pharmaceuticals Inc has shown fluctuations over the years. In 2020, the ratio was 1.19, indicating that the company generated $1.19 in revenue for every dollar of working capital. This ratio improved in 2021 to 1.59, suggesting increased efficiency in utilizing working capital to generate sales.

However, there was a significant decline in the ratio in 2022, dropping to 0.95, which could indicate potential inefficiencies in managing working capital during that period. The ratio further decreased in 2023 to 0.81, indicating a continued decline in revenue generation relative to working capital.

In 2024, there was a slight improvement with the ratio increasing to 0.97, but it still remained below the levels seen in 2020 and 2021. Overall, the working capital turnover ratio for Regeneron Pharmaceuticals Inc has been volatile, suggesting fluctuations in the company's ability to efficiently convert working capital into sales over the years.